Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Kidney Int. 2018 Oct 6;94(6):1151–1159. doi: 10.1016/j.kint.2018.06.031

Table 1.

Serology of ADR injected and Col4a3 knockout mice.

FSGS Alport syndrome
CTRL ADR CD ADR+CD Col4a3+/+ NS Col4a3+/+ CD Col4a3−/− NS Col4a3−/− CD
Cholesterol, mg/dL 92.7±2.7 113.2±14.7 89.8±0.3 120.3±13.0& 117.9±3.4 131.3±4.7 203.5±10.0*** 145.5±7.6**
HDL mg/dL 51.7±22.4 98.2±17.1 57.0±10.4 112.0±12.3 129.8±6.7 137.0±6.1 162.8±6.7# 138.3±5.4*
LDL mg/dL BDL −5.0±3.7 BDL −3.3±0.5 5.4±0.3 5.8±0.9 14.9±1.2# 10.0±2.0
Triglycerides mg/dL 46.7±15.5 83.0±8.6 54.0±5.0 58.3±3.8 61.6±2.9 63.0±2.8 81.6±6.6 98.3±17.0
VLDL mg/dL 12.0±2.0 15.4±1.9 11.0±1.1 11.7±0.9 14.6±1.4 16.0±1.4 13.7±1.0 19.8±3.5*

Data are mean ± SD. ADR – adriamycin; CD – 2-hydroxypropyl-β-cyclodextrin (HPβCD); CTRL – control; NS – normal saline solution; HDL – high density lipids, LDL – low density lipids; VLDL – very low density lipids; BDL – below detection level.

*

p<0.05

**

p<0.01, when comparing CD treated vs. non-treated

#

p<0.01

***

p<0.001, when comparing knockout vs. controls

&

p<0.05, when comparing ADR+CD vs. CD group.